GlassScriptPhysician profile
Edgar Rene Blecker
NPI 1134616949
$3,622.62
in general payments reported to CMS, 2019-2025
27 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $15.26 · 2021: $887 · 2022: $973 · 2023: $674 · 2024: $415 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,572.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $680.70 | 2021-2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $666.23 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $481.55 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $299.08 | 2021-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $191.39 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $182.72 | 2021-2023 | |
| Medtronic, INC. | $175.37 | 2022-2024 | Na, Minimed 780g |
| Silk Road Medical, INC. | $148.80 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Lilly USA, LLC | $98.09 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Mylan Specialty L.P. | $95.92 | 2023-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $88.17 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $58.40 | 2019 | |
| Abbvie INC. | $56.91 | 2022-2023 | Vraylar |
| Insmed, INC. | $53.86 | 2025 | Arikayce |
| Eisai INC. | $44.30 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.16 | 2023 | Tradjenta, Stiolto Respimat |
| Pulmonx Corporation | $35.29 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.37 | 2019-2023 | Xifaxan |
| Tetraphase Pharmaceuticals, INC. | $30.80 | 2019 | |
| Pfizer INC. | $28.50 | 2019-2025 | |
| Inspire Medical Systems, INC. | $23.01 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.26 | 2025 | Caplyta |
| Philips North America LLC | $21.01 | 2024 | (Ak6) Vest Therapy |
| Verona Pharma, INC. | $18.89 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $16.51 | 2023 | Nuzyra |
| Janssen Pharmaceuticals, INC | $15.26 | 2020 | |
| Esperion Therapeutics, INC. | $14.07 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Blecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.